Dravet Syndrome Market Size, Share and Global Trend By Treatment (Drugs, Vagus Nerve Stimulation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecast, 2024-2032

Dravet syndrome is referred to as a severe type of epilepsy that is characterized by the often triggering through the occurrence of fevers or high temperature. Dravet syndrome is an extremely rare dysfunction of the brain and is often a lifelong condition. The time of the onset of the disease is the first year of childhood in an otherwise healthy infant, and as time progresses, several other types of seizures occur.

According to the Dravet Foundation, it was determined that the Dravet syndrome occurs in 1 in 15,700 infants born in the U.S. The Food and Drug Administration (FDA) approval of stiripentol (Diacomit) for the treatment of patients suffering from the Dravet syndrome aged two years and older and are already taking clobazam.

In June 2018, the FDA also approved epidiolex (cannabidiol), the first FDA approved drug containing a purified drug substance derived from marijuana. These recent approvals are further contributing to the accelerated growth of the market, due to the greater research & development efforts being undertaken. These factors are anticipated to contribute to the positive Dravet syndrome market growth.

One of the key market drivers of the Dravet syndrome market growth is the recent regulatory approvals for the treatment and management of the disorder. Some of the recent regulatory approvals include stiripentol (Diacomit) and also epidiolex for the management of a variety of symptoms associated with the disorder.

At the same instance, several newer applications for the regulatory approval such as the submission of a new drug application (NDA) by Zogenix for its drug candidate ZX008 (Fintepla), is also anticipated to contribute towards the accelerated growth of the market. Apart from these, several drug candidates are also undergoing clinical trials at various stages.

The factor that is expected to inhibit the growth of the market is the adverse effects associated with Dravet syndrome products. For instance, some of the side effects include increased drowsiness, agitation, impaired coordination, loss of muscle tone, nausea, depressive thoughts, and feelings, amongst others. This may make the medications unsuitable for some kinds of patients. Regulatory and clinical hurdles might also impact the global Dravet syndrome market growth due to delays in product approvals.

Key Players Covered

The major companies covered in the global Dravet syndrome market report include Epygenix Therapeutics, Inc., Ovid Therapeutics, GW Pharmaceuticals plc., Takeda Pharmaceutical Company Limited., Zogenix and PTC Therapeutics, and other players.

SEGMENTATION 

As per the current Dravet syndrome market trends, at present, drugs account for the largest proportion of the market, and this is because of the recent regulatory approvals and the majority of the treatment options consisting of drugs of classes of anticonvulsants, benzodiazepines, cannabinoids, and others. Vagus Nerve Stimulations (VNS) are also approved as a form of treatment, and in some instances, there are used in patients who do not respond to medications alone.

Key Insights

• Prevalence of Dravet Syndrome by Key Countries


• Regulatory Scenario for Key Countries


• Advancements in Research & Development of Treatment Options


• Pipeline Analysis


• Overview of Advances in Novel Therapeutics


• New Product Launches

Regional Analysis

The global Dravet Syndrome market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe, are the two largest markets for Dravet Syndrome at present, and they are expected to account for a large proportion of the market in the forecast period as well. In 2018, the Food and Drug Administration (FDA) approved stiripentol and epidiolex, for the treatment of the Dravet syndrome. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. This is due to the increased awareness of the disorder, the ongoing R&D efforts, and the prevalence of the disorder in the country. Additionally, Dravet Syndrome market in Latin America and the Middle East and Africa is in the nascent stage; however, unmet needs for Dravet syndrome treatment is expected to drive the market growth in this region.

Dravet Syndrome Industry Developments

• In August 2018, the FDA approved stiripentol (Diacomit) for the treatment of the Dravet syndrome for the patients aged 2 and older and who are already taking clobazam
• In June 2018, the FDA approved Epidiolex (cannabidiol) for the treatment of the Dravet syndrome, and this is the first ever drug approved to be derived from the cannabis.
• In February 2019, Zogenix submitted the new drug application (NDA) for the treatment of the Dravet syndrome. This treatment consists of a low dosage fenfluramine therapy for the treatment of the Dravet syndrome’s seizures